Enliven Therapeutics, Inc. ELVN 深 滬
已收盤 02-06 16:00:00 美东时间
29.42
+2.430
+9.00%
華盛通- 最 高30.22
- 今 開27.45
- 成交量 126.33万股
- 最 低 27.125
- 昨 收 26.99
- 總市值 17.46亿
- 52周最高 30.22
- 市盈率 靜 --
- 換手率 2.13%
- 52周最低 13.30
- 委 比 96.68%
- 總股本 5934.73万
- 歷史最高 250.84
- 量 比 1.20
- 振 幅 11.47%
- 歷史最低 3.896
- 每 手 1
- 風險率 2.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 脑再生科技涨超120%，马斯克“量产预告”催化脑机概念行情；Alumis周涨近120%
ANPA周涨近300%，公司获私募大额股份认购；脑再生科技涨超120%，马斯克“量产预告”催化脑机概念行情；Alumis周涨近120%，治疗银屑病新药临床成功>>
01-10 06:27
美股牛股 | 获FDA支持加速药物上市！MoonLake大涨27%；Satellogic大涨21.7%
获FDA支持加速药物上市！MoonLake大涨27%；宣布获七位数地球观测合同，Satellogic涨超21%>>
01-09 16:01
Enliven Therapeutics Announces Initial Data From Ongoing Phase 1b ENABLE Clinical Trial Evaluating ELVN-001 In Patients With CML That Is Relapsed, Refractory Or Intolerant To Available TKIs
Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohortsELVN-001 continues to demonstrate a favorable safety and
01-08 22:08
美股周涨跌榜 | “减肥神药”临床数据引爆！WaVe生命科学周涨121%；太空概念股Planet Labs周涨42.8%
“减肥神药”临床数据引爆！WaVe生命科学周涨121%；福尼克斯周内飙升50%，创历史新高；SpaceX上市传闻引爆市场，太空概念股Planet Labs周涨42.8%>>
2025-12-13 10:07
Enliven Therapeutics Appoints Rick Fair As CEO And Member Of Board Of Directors, Effective Immediately
Rick Fair, a seasoned executive with deep experience developing and commercializing hematology products, joins Enliven as Chief Executive OfficerCo-Founder Sam Kintz will assume a new position as Head of PipelineBOULDER,
2025-12-11 22:04
Enliven's ELVN-001 Shows Anti-CML Activity In Patients With Atypical Fusion Transcripts; Will Present Data From The Ongoing ENABLE Phase 1a/1b Clinical Trial Of ELVN-001 On A Subset Of Chronic Myeloid LeukemiaPatients At The ASH 2025 Annual Meeting
ELVN-001 demonstrates encouraging anti-CML activity in heavily pretreated patients with atypical fusion transcriptsGrowing unmet need for patients with atypical transcript e13a3, which is resistant to TKIs targeting the
2025-11-03 22:09
Enliven Therapeutics Q2 EPS $(0.49) Beats $(0.54) Estimate
Enliven Therapeutics (NASDAQ:ELVN) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.54) by 9.26 percent. This is a 19.51 percent decrease over losses of $(0.41) per share
2025-08-14 04:25
美股大行评级 | 潜在涨幅336.36%！Canaccord Genuity上调ATAI Life Sciences目标价至12美元，维持"买入"评级
Redburn Atlantic：下调Adobe(ADBE)评级至"卖出"，目标价从420美元降至280美元
2025-07-03 11:01
HC Wainwright & Co. Maintains Buy on Enliven Therapeutics, Raises Price Target to $48
HC Wainwright & Co. analyst Robert Burns maintains Enliven Therapeutics (NASDAQ:ELVN) with a Buy and raises the price target from $40 to $48.
2025-07-02 18:47
美股大行评级 | 超配！Hinge Health获多家大行首予评级； Oppenheimer上调Mate目标价从665美元升至775美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1141651881139785729.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Ascendiant Capital：维持SurgePays Inc(SURG)"买入"评级，目标价从8.75美元升至9美元</p> <p>• Ascendiant Capital：维持LiqTech Internatio
2025-06-17 09:46
